Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once-weekly vs Norditropin daily in Chinese children with growth hormone deficiency
2020-002974-28Phase 3
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2020-002974-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002974-28.